| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Medicine, Kashiwa City Hospital (T.Y., T.N., Y.I., A.T.), Kashiwa, Chiba 277; Department of Medicine, Dokkyo Koshigaya Hospital, Dokkyo University School of Medicine (A.S.), Koshigaya, Saitama 343-8555; Second Department of Medicine, Faculty of Medicine, University of the Ryukyus (I.K.), Nishihara, Okinawa 903-0215; and First Department of Medicine, University of Occupational and Environmental Health (S.E., Y.T.), Yawatanishiku, Kitakyushu 807-8555, Japan
Address all correspondence and requests for reprints to: Akira Sato, M.D., Department of Medicine, Dokkyo Koshigaya Hospital, Dokkyo University School of Medicine, Koshigaya, Saitama 343-8555, Japan. E-mail: asato{at}dokkyomed.ac.jp
In hyperthyroid Graves disease, short-term methimazole is sufficient to induce lasting remission in some patients, but even long-term treatment fails to do so in others. We have evaluated the role of autoimmune abnormalities in the helper T cell type 2 (TH2)-interleukin-13 (IL-13)-TSH receptor system in maintaining hyperthyroidism by comparing IgE levels in patients with various thyroid diseases.
One hundred and ninety-three patients with hyperthyroid Graves
disease were treated with methimazole, and blood samples were
obtained to measure serum levels of T4,
T3, TSH, thyroglobulin, antimicrosomal antibody, TSH
binding inhibitory Ig (TBII), thyroid-stimulating antibody, thyroid
stimulation-blocking antibody, IgE, interferon-
, IL-4, and IL-13.
Elevation of serum IgE (
170 U/mL) was found in 35.5% of patients
with hyperthyroid Graves disease, and serum levels of T4,
T3, antimicrosomal antibody, and TBII were significantly
greater in patients with IgE elevation than in those with normal serum
IgE. During methimazole treatment, there was a parallel decrease in the
serum T4 concentration in the presence or absence of an IgE
elevation. However, there was a significantly smaller decrease in TBII
in patients with elevated IgE than in those with normal IgE. As a
result, the remission rate was significantly greater in patients with
normal IgE than in those with IgE elevation. Serum levels of IL-13 were
elevated in 64.7% of patients with IgE elevation in the absence of
detectable TH1 marker, interferon-
.
These findings suggest that in one third of patients with hyperthyroid Graves disease, TH2 cells are stimulated and secrete excess amounts of IL-13, which subsequently stimulates B cells to synthesize more TSH receptor antibody and IgE, so that during methimazole treatment TBII decreases less in patients with IgE elevation, producing a lower remission rate.
This article has been cited by other articles:
![]() |
Y. Hiromatsu, T. Fukutani, M. Ichimura, T. Mukai, H. Kaku, H. Nakayama, I. Miyake, S. Shoji, Y. Koda, and T. Bednarczuk Interleukin-13 Gene Polymorphisms Confer the Susceptibility of Japanese Populations to Graves' Disease J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 296 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-R. Chen, H. Aliesky, P. N. Pichurin, Y. Nagayama, S. M. McLachlan, and B. Rapoport Susceptibility Rather than Resistance to Hyperthyroidism Is Dominant in a Thyrotropin Receptor Adenovirus-Induced Animal Model of Graves' Disease as Revealed by BALB/c-C57BL/6 Hybrid Mice Endocrinology, November 1, 2004; 145(11): 4927 - 4933. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nagayama, H. Mizuguchi, T. Hayakawa, M. Niwa, S. M. McLachlan, and B. Rapoport Prevention of Autoantibody-Mediated Graves'-Like Hyperthyroidism in Mice with IL-4, a Th2 Cytokine J. Immunol., April 1, 2003; 170(7): 3522 - 3527. [Abstract] [Full Text] [PDF] |
||||
![]() |
O M P JOLOBE Thyroid disorders{---}an update Postgrad. Med. J., February 1, 2001; 77(904): 144 - 144. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |